INVENTIVA: Inventiva reports its 2022 first-half financial results and provides a corporate update
Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021 Receipt of a €4 million milestone payment from Inventiva's partner AbbVie for cedirogant Phase IIb